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ABSTRACT
To assess the effects of long-term continuous GH treatment on body
composition, blood pressure (BP), and lipid metabolism in children
with short stature born small for gestational age (SGA), body mass
index (BMI), skinfold thickness measurements, systemic BP mea-
surements, and levels of blood lipids were evaluated in 79 children
with a baseline age of 3–11 yr with short stature (height SD-score,
,21.88) born SGA (birth length SD-score, ,21.88). Twenty-two of the
79 children were GH deficient (GHD). All children participated in a
randomized, double-blind, dose-response multicenter GH trial. Four-
and 6-yr data were compared between two GH dosage groups (3 vs.
6 IU/m2 body surface/day).
Untreated children with short stature born SGA are lean (mean
BMI SD-score, 21.3; mean SD-score skinfolds, 20.8), have a higher
systolic BP (SD-score, 0.7) but normal diastolic BP (SD-score, 20.1),
and normal lipids (total cholesterol, 4.7 mmol/L; low-density li-
poprotein, 2.9 mmol/L; high-density lipoprotein, 1.3 mmol/L) com-
pared with healthy peers. During long-term continuous GH treat-
ment, the BMI normalized without overall changes in sc fat
compared with age-matched references, whereas the BP SD-score
and the atherogenic index decreased significantly. Although the
mean 6-yr increase in height SD-score was significantly higher in
the children receiving GH treatment with 6 IU/m2zday (2.7) than
in those receiving treatment with 3 IU/m2zday (2.2), no differences
in the changes in BMI, skinfold measurements, BP, and lipids were
found between the GH dosage groups. The pretreatment SD-scores
for BMI, skinfold, and BP, as well as the lipid levels, were not
significantly different between GHD and non-GHD children, but
after 6 yr of GH treatment the skinfold SD-score and BP SD-score
had decreased significantly more in the GHD than in the non-GHD
children.
Our data indicate that GH treatment has at least up to 6 yr positive
instead of negative effects on body composition, BP, and lipid me-
tabolism. In view of the reported higher risk of cardiovascular dis-
eases in later life in children born SGA, further research into adult-
hood remains warranted. (J Clin Endocrinol Metab 85: 3786–3792,
2000)
SHORT STATURE IN children born small for gestationalage (SGA) is a well known phenomenon. Although
postnatal catch-up growth occurs in most of the SGA new-
borns, about 15% of these children fail to show catch-up
growth, resulting in short adult stature in most of the cases
(1–5). The mechanism of the stunted postnatal growth in
short children born SGA is poorly understood. It has been
previously shown that disturbances in the GH/insulin-like
growth factor I axis may account for some of the growth
retardation: up to 60% of the short children born SGA have
GH-secretory abnormalities and/or reduced levels of insu-
lin-like growth factors (6–12). Studies have shown that con-
tinuous or discontinuous treatment with recombinant hu-
man GH in varying dosages accelerates growth significantly
in short children born SGA, resulting in catch-up growth to
values within the normal range, followed by growth along
their target height percentile (7, 13–21).
SGA has been associated with increased prevalence of
diabetes mellitus type II, hypertension, and hyperlipidemia
at a relative young age in later life (22). All three disorders
are risk factors of cardiovascular diseases. Concern has been
expressed regarding possible adverse effects of long-term
GH treatment during childhood. A previous study by our
group showed that in short children born SGA either with or
without GH deficiency long-term treatment with supra-
physiological GH dosages caused a relative insulin resistance
(22a), similar to findings in other GH-treated patient groups
(23, 24). Because relative insulin resistance is associated with
the development of diabetes type II, follow-up of these chil-
dren during long-term GH treatment is required. Data on
possible effects of GH treatment on other risk factors for
cardiovascular diseases during childhood are very limited in
SGA children.
To assess the body composition, blood pressure (BP), and
lipid metabolism in children with short stature born SGA
before and during long-term continuous GH treatment, the
body mass index (BMI), skinfold measurements, systolic and
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diastolic BP, and levels of blood lipids were evaluated in 79
children with short stature born SGA with or without GH
deficiency, participating in a randomized, double-blind,
dose-response multicenter GH trial (21). We now report 4- to




Seventy-nine prepubertal short children born SGA were included
after meeting the following criteria: 1) birth length sd-score below 21.88
(i.e. less than the third percentile) for gestational age (25); 2) chrono-
logical age (CA) between 3 and 11 yr in boys and 3 and 9 yr in girls at
the start of the study; 3) height sd-score for CA (height sd-scoreCA) below
21.88 (26); 4) height velocity sd-score for CA less than or equal to zero
(26) to exclude children presenting spontaneous catch-up growth; 5)
prepubertal, defined as Tanner breast stage I for girls and testicular
volume less than 4 mL for boys (27); and 6) uncomplicated neonatal
period [i.e. without signs of severe asphyxia (defined as an Apgar score
below 3 after 5 min), without sepsis neonatorum, and without long-term
complications of respiratory ventilation]. Exclusion criteria were: endo-
crine or metabolic disorders, chromosomal disorders, growth failure
caused by other disorders or syndromes (emotional deprivation, severe
chronic illness, chondrodysplasia), and previous or present use of drugs
that could interfere with GH treatment. Patients with Silver-Russell
syndrome (SRS), however, were included in this study. GH deficiency
was defined as a peak GH secretion less than 10 mg/L during two GH
provocation tests or during one provocation test and a 24-h GH profile.
GH deficiency was not an exclusion criterium.
Four centers in The Netherlands participated in the study. The study
was approved by the Ethics Committee of each participating center.
Written informed consent was obtained from the parents or custodians
of each child.
Study design
Before GH treatment, 40 of the 79 children underwent a 24-h plasma
GH profile, as described previously (6). To stratify for the spontaneous
GH secretion during the 24-h GH profile, the total group of 79 children
was divided into three groups: “normal profile,” “GH-insufficient pro-
file” (area under the curve ,90 mg/L/24 h and mean GH ,2.0 mg/L),
and “no profile performed.” After stratification for spontaneous GH
secretion during the 24-h GH profile and CA (3.00–5.99, 6.00–8.99, and
9.00–10.99 yr), all children were randomly and blindly assigned to either
one of two GH dosage groups: group A, 3 IU/m2 body surfacezday; or
group B, 6 IU/m2 body surfacezday (’0.1 or 0.2 IU/kgzday, respectively)
(6, 21). Biosynthetic GH (recombinant human GH Norditropin; Novo
Nordisk A/S, Bagsvaerd, Denmark) was given sc once daily at bedtime
with a pen injection system (Nordiject 24; Novo Nordisk A/S). Every 3
months the total GH dose was adjusted to the calculated body surface.
The study was kept double-blind by using an equal volume of a recon-
stituted preparation. Criteria to discontinue the GH treatment were a
height velocity below 0.5 cm over the last 6 months and/or bone age 15
yr or more for girls and 16.5 yr or more for boys.
Before the start of treatment and every 3 months after the start of GH
treatment, all children were seen at their local hospital for a physical
examination, including measurements of standing height and weight.
Height was expressed as sd-score (21). BMI [weight (kilogram)/height
(meter squared)] was expressed as sd-score for sex and CA (21). The
thickness of four skinfolds (biceps, triceps, subscapular, and suprailia-
cal) were measured according to Cameron (28). The measurements of all
children were performed by two trained observers (W. de Waal, and
later on T.S.) using a Holtain skinfold caliper. Two measurements per
visit were made, and the mean was used for the analysis. The sum of the
four skinfold measurements were expressed as sd-score using the ref-
erences for healthy Dutch children (29). To calculate sd-scores, data of
the reference population were transformed using the LMS method (30,
31). This method transforms the reference data at each age to a normal
distribution. Pubertal stages were assessed by the same two investiga-
tors according to Tanner (27), using an orchidometer in boys.
Every 6 months BP was measured. Systolic and diastolic BP was
determined with a single Dynamap Critikon 1846SX (Critikon, Inc.,
Tampa, FL) with the children in a sitting position using a cuff size
corresponding to the size of their arm. BP was expressed as sd-score,
using age- and sex-specific reference values (age-matched reference
values; BPage) (32). As described previously, a child was considered
normotensive if BP was below the 90th percentile. Because body size is
the most important determinant of BP in childhood and adolescence,
additionally, we adjusted the pretreatment BP values and those after 6
yr of GH treatment for height-matched reference values (BPheight) (32).
During the first 4 yr, once a year, blood samples were collected for
the determination of total cholesterol (TC), low-density lipoprotein
(LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol.
Dutch age-matched reference values were used for TC and HDL cho-
lesterol (33). For the other lipids, our own reference values of healthy
children were used (34). The atherogenic index was calculated as the
ratio of TC/HDL cholesterol.
Assays
Lipid analysis was subject to the quality-assessment program of the
World Health Organization Regional Lipid Reference Center (Prague,
Czech Republic). The TC level was measured using an automated en-
zymatic method (35) with the CHOD-PAP High Performance reagent kit
(Boehringer Mannheim, Mannheim, Germany). HDL and LDL choles-
terol were measured by the same method after precipitation. For HDL
cholesterol, the phosphotungstate method of Burstein was modified (36).
LDL cholesterol precipitation was performed with polyvinylsulfate
(Boehringer Mannheim). The overall coefficient of variance for TC, HDL
cholesterol, and LDL cholesterol was 2.9%, 3.7%, and 5.8%, respectively.
Statistical analyses
Because the study remains double-blind until final height, statistical
analysis was performed by an independent statistician (P.M.), and,
therefore, data are only summarized as mean and sd, unless indicated
otherwise. The sd-scores of the pretreatment values and after 6 yr of GH
treatment were compared with zero using Student’s one-sample t tests.
Differences between points in time were tested by paired Student’s t
tests. Differences between groups were tested using Student’s two-
sample t tests. To compare pretreatment levels or changes during GH
treatment between the GH-deficient (GHD) children and the non-GHD
children, multiple linear regression analyses were performed, with ad-
justment made for baseline covariables. For these analyses, pretreatment
age and birth length sd-scores were chosen as baseline covariables along
with GH deficiency (yes/no); the changes during treatment were, in
addition, adjusted for the GH dose. A P value less than 0.05 was con-
sidered significant.
Results
Table 1 lists the pretreatment clinical data of the 79 chil-
dren. Both GH dosage groups had similar initial character-
istics. Seven children had SRS. Twenty-two children were
GHD (Table 2). During the first 5 yr, five children dropped
out of the study for the following reasons long before reach-
TABLE 1. Mean (SD) pretreatment data for each GH dosage
group
Group A 3 IU
GH/m2zday
(n 5 41)




Gestational age (week) 37.3 (3.2) 36.0 (4.1)
Birth length SD score 23.6 (1.4) 23.7 (1.7)
Birth weight SD score 22.6 (1.2) 22.6 (1.0)
CA (yr) 7.3 (2.1) 7.2 (2.4)
Height SD score 23.0 (0.7) 23.1 (0.7)
Target height SD score 21.0 (0.9) 20.5 (0.9)
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ing adult height: treatment of early puberty (n 5 1), signs of
GH insensitivity and no catch-up growth (n 5 1), and prob-
lems with motivation to inject GH (n 5 3). These five children
were lost to follow-up after discontinuation of GH. After 6 yr
of GH treatment, in five adolescents GH treatment was dis-
continued because (near) adult height was reached. Only
data obtained during the GH treatment period were included
in the analysis. After 6 yr of GH treatment, 17 children were
still prepubertal.
Height, BMI, and skinfolds
The height sd-score increased significantly during GH
treatment (P , 0.001). The mean (sd) 6-yr increment in height
sd-score was significantly higher in group B compared with
group A [from 23.1 (0.7) to 20.4 (1.1) in group B vs. from
23.0 (0.7) to 20.8 (0.6) in group A; P 5 0.044]. The 6-yr
increment in height sd-score was not significantly different
between the GHD and non-GHD children.
Figure 1 shows the BMI sd-score during 6 yr of GH treat-
ment. The pretreatment mean BMI sd-score of the children
was significantly lower than zero. During GH treatment, BMI
sd-score increased significantly (P , 0.001) to values being
not significantly different from zero. The increment in BMI
sd-score was not significantly different between the GH dos-
age groups. Although the pretreatment BMI sd-score in the
GHD group was higher than in the non-GHD group, this
difference was not statistically significant. The increase in
mean (sd) BMI sd-score was not significantly different be-
tween the GHD group and the non-GHD group [from 20.8
(1.4) to 20.2 (1.4) vs. from 21.4 (1.2) to 20.1 (0.9)].
Figure 2 shows the sd-scores of the sum of the four skin-
folds during 6 yr of GH treatment. In one very obese boys it
was not possible to measure the skinfolds appropriately dur-
ing the study period. The data of all other children were used
for this analysis. The pretreatment sd-scores were signifi-
cantly lower than zero (P , 0.001). During the first year, the
sd-scores decreased significantly (P , 0.001). Thereafter, the
mean sd-score increased significantly (P , 0.001) to a value
being not significantly different from pretreatment values,
but still significantly less than zero (P , 0.001). No differ-
ences in the changes of the sd-scores over time were found
between the two GH dosage groups. Although the pretreat-
ment mean sd-score in the GHD group was slightly higher
than in the non-GHD group, this difference was not statis-
tically significant. In the GHD group, the mean (sd) skinfold
sd-score showed a trend toward lower values after 6 yr of GH
treatment [from 20.5 (1.1) to 20.9 (0.5); this change was
significantly different (P 5 0.044) from the 6-yr change in the
non-GHD group (from -1.0 (1.1) to -1.0 (0.9)].
BP
Figure 3 shows the sd-scores of BPage (using age-matched
reference values) before treatment and during treatment, as
well as the BPheight sd-scores (using height-matched refer-
ences values) before treatment and after 6 yr of treatment.
The mean pretreatment systolic BPage sd-score was signifi-
cantly higher than zero, whereas the mean diastolic BPage
sd-score was significantly lower than zero (Table 3). During
6 yr of GH treatment, systolic BPage decreased significantly
to values not significantly different from zero, whereas di-
astolic BPage decreased significantly to values significantly
lower than zero. The decrease in the systolic BPage sd-score
FIG. 1. Mean (SD) BMI SD-score before and during 6 yr of GH treat-
ment for group A (f) and for group B (M).
TABLE 2. Mean (SD) pretreatment data for the GHD group as





GH dosage group A/B 13/9 28/29
Birth length SD score 23.1 (1.0) 23.8 (1.6)
Birth weight SD score 22.4 (1.0) 22.7 (1.1)
CA (yr) 8.1 (1.6) 7.0 (2.3)
Height SD score 23.0 (0.6) 23.1 (0.7)
FIG. 2. Mean (SD) skinfold SD-score before and during 6 yr of GH
treatment for group A (f) and for group B (M).
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was particularly seen during the last 3 yr of the study period.
The mean pretreatment systolic BPheight sd-score was even
higher than that of systolic BPage, whereas, in contrast to the
diastolic BPage sd-score, the mean diastolic BPheight sd-score
was not significantly different from zero (Table 3). Conse-
quently, before treatment, about a quarter of the children had
a systolic BP above the 90th percentile using height-matched
reference values. After 6 yr of GH treatment, a similar change
was found for the sd-scores of BPheight as for the BPage sd-
scores. No differences in the BP changes were found between
GH dosage groups. The pretreatment BPage sd-score was not
significantly different between the GHD and non-GHD chil-
dren. The changes in the systolic BP sd-score as well as in the
diastolic BP sd-score during GH treatment were significantly
higher in the GHD group than in the non-GHD group: mean
(sd) systolic BPage sd-score from 0.8 (0.8) to 0.0 (1.1) vs. 0.3
(1.2) to 0.1 (1.0), P 5 0.037; diastolic BPage sd-score from 20.2
(0.9) to 21.0 (0.8) vs. from 20.5 (1.0) to 20.8 (0.7), P 5 0.014.
Lipids
Figure 4 shows the levels of TC, LDL cholesterol, and HDL
cholesterol. Table 4 shows the lipid levels before and after 4
yr of GH treatment. The pretreatment mean levels of the lipid
profiles were normal. Three children (3.8%) had TC more
than 6 mmol/L, seven children (8.9%) had LDL cholesterol
more than 3.7 mmol/L, and two children (2.6%) had HDL
cholesterol less than 0.9 mmol/L. After 4 yr of GH treatment,
none of the children had an abnormal TC, whereas three
(4.1%) of the children had LDL cholesterol more than 3.7
mmol/L and three children (3.8%) had HDL cholesterol less
than 0.9 mmol/L. During 4 yr of GH treatment, TC, LDL
FIG. 3. Mean (SD) systolic BP SD-score (left) and diastolic BP SD-score (right), using age-matched reference values (BPage), before and during
6 yr of GH treatment for group A (f) and for group B (M). On the right part of each panel is the BP SD-score using height-matched reference
values (BPheight) before and after 6 yr of GH treatment.
TABLE 3. Mean (SD) of BP levels before and after 6 yr of GH treatment
Pretreatment After 6 yr
Group A Group B Group A 1 B Group A Group B Group A 1 B
Systolic BP (mm Hg) 103 (13) 101 (13) 102 (13) 109 (13) 108 (12) 109 (12)
Diastolic BP (mm Hg) 57 (10) 56 (9) 56 (10) 57 (7) 56 (7) 57 (7)
Systolic BPage SD score 0.5 (1.2) 0.3 (1.1) 0.4 (1.1)
a 0.1 (1.1) 0.0 (0.9) 0.0 (1.0)b
no (%) .P90 14 (17.7%) 4 (5.8%)
Diastolic BPage SD score 20.4 (1.0) 20.4 (0.9) 20.4 (1.0)
a 20.8 (0.7) 20.9 (0.8) 20.9 (0.8)c,d
no (%) .P90 4 (5.1%) 1 (1.4%)
Systolic BPheight SD score 0.8 (1.1) 0.6 (1.1) 0.7 (1.1)
c 0.2 (1.1) 0.1 (1.0) 0.2 (1.0)e
no (%) .P90 20 (25.3%) 5 (7.2%)
Diastolic BPheight SD score 20.1 (1.2) 20.2 (0.9) 20.1 (1.0) 20.8 (0.7) 20.9 (0.7) 20.8 (0.7)
c,d
no (%) .P90 6 (7.6%) 1 (1.4%)
BPage SD score, SD score using age-matched reference values; BPheight SD score, SD score using height-matched reference values; P90, 90th
percentile.
Significantly different from zero: a P , 0.005; c P , 0.001.
Significantly different from pretreatment values: b P , 0.05; d P , 0.001; eP , 0.01.
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cholesterol, and the atherogenic index significantly de-
creased, whereas HDL cholesterol remained unchanged. The
changes in lipid levels were not significantly different be-
tween the GH dosage groups. In the GHD group, similar
results were found as in the non-GHD group: mean (sd) TC
from 4.9 (0.9) to 4.5 (0.7) mmol/L, LDL cholesterol from 2.9
(0.8) to 2.6 (0.7) mmol/L, and HDL cholesterol from 1.4 (0.3)
to 1.4 (0.3) mmol/L vs. TC from 4.6 (0.7) to 4.2 (0.6) mmol/L,
LDL cholesterol from 2.9 (0.7) to 2.4 (0.6) mmol/L, and HDL
cholesterol from 1.3 (0.3) to 1.3 (0.3) mmol/L.
Subgroups
Children who remained prepubertal throughout the
whole study period showed similar patterns in BMI, skinfold
thicknesses, BP, and lipids as the whole study group. The
data of the children with SRS were also comparable with the
total study group. During GH treatment similar patterns of
the results were found in boys as in girls (data not shown).
Discussion
Our study is the first demonstrating data on body com-
position and BP, as well as lipids, before and during long-
term continuous GH treatment in children with short stature
born SGA either with or without GH deficiency. In short
children born SGA, height, BMI, and the thickness of the
skinfolds were lower than age-matched controls. Whereas
the height sd-score and BMI sd-score increased significantly
during 6 yr of GH treatment, the skinfolds measurements
showed an initial decrease in sd-score, followed by an in-
crease to pretreatment levels, thereby still remaining signif-
icantly lower than age-matched reference values. The
changes in body composition during GH treatment were not
significantly different between the GH dosage groups. Thus,
short children born SGA have a low weight compared to
height and have a relatively low body fat percentage. During
6 yr of GH treatment, the catch-up in height was accompa-
nied by an increase in body weight for height, without an
overall change in body fat percentage compared with healthy
controls. Before treatment, 28% of the patients were consid-
ered GHD. A previous study describing the 5-yr data on
height showed that the growth response on long-term GH
treatment was comparable between the GHD children and
the non-GHD children (21). In the present study, we found
that the pretreatment BMI sd-score and the skinfold sd-score
of the GHD children were not significantly different from the
non-GHD children. During GH treatment, a similar change
of the BMI sd-score was found for the GHD children as for
the non-GHD children, whereas the small decrease in skin-
fold sd-score in the GHD children over 6 yr was significantly
greater than in the non-GHD group.
Our data are comparable with the results of the fat and
muscle measurements using magnetic resonance imaging
described by Leger et al. (37). They reported an increase in
muscle tissue cross-sectional area in 14 prepubertal short
children born SGA without GH deficiency during 3 yr of GH
treatment with 0.2 IU/kgzday (’6 IU/m2zday). In addition,
the adipose tissue cross-sectional area showed an initial de-
crease during the first year of treatment, followed by an
increase in the second and third years to values similar as to
a control group of seven healthy children (37).
Several earlier reports have demonstrated the negative
relationship between birth weight and BP in childhood as
well as in adulthood (22, 38–40). Therefore, the SGA children
may be more at risk of hypertension in later life than their
healthy peers. To optimize GH treatment in children with
short stature born SGA, supraphysiological GH doses are
given for a long period during childhood. Because in adults
GH hypersecretion in acromegaly is associated with an in-
creased incidence of hypertension (41), concern has been
expressed regarding possible negative effects of long-term
GH treatment in these children. We showed that pretreat-
ment systolic BP was significantly higher than age-matched
as well as height-matched reference data, whereas pretreat-
ment diastolic BP was significantly lower compared with
age-matched reference data, but not significantly different
compared with height-matched reference data. During GH
treatment, the sd-scores of systolic and diastolic BP de-
creased significantly. After 6 yr, systolic BP was not different
from controls anymore, whereas diastolic BP was even lower
than healthy age-matched and height-matched controls. The
changes in the BP sd-scores were not significantly different
between the GH dosage groups. The GHD children showed
a significantly greater decrease in BP sd-score than the non-
GHD children, resulting in similar BP sd-scores after 6 yr in
these two groups. Barton et al. (42) described that in contrast
to adult subjects, treatment with a high dose of GH in short
children is not associated with activation of the renin-angio-
tensin-aldosterone system (42). This suggests that it is un-
likely that GH treatment in childhood is associated with the
increased risk of hypertension seen in adults with GH hy-
persecretion. Our long-term data support these findings by
showing even a decrease in the BP sd-scores during treat-
ment with GH in dosage up to 6 IU/m2zday.
GH deficiency is associated with dyslipidemia (43, 44).
FIG. 4. Mean (SD) levels of TC (squares), LDL cholesterol (triangles),
and HDL cholesterol (circles) before and during 4 yr of GH treatment
for group A (filled symbols) and for group B (open symbols).
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Barker et al. (22) demonstrated the negative correlation be-
tween birth weight and syndrome X (hypertension, diabetes
mellitus type II, and hyperlipidemia) in adult men. Conse-
quently, the children of our study seem to be at risk of
problems with lipid metabolism in later life. In the present
study, we showed that children with short stature born SGA
had normal mean pretreatment lipid values. In addition, no
differences in lipids were found between the GHD and the
non-GHD SGA children. No previously published data are
available about the effects of GH treatment on lipids in chil-
dren with short stature born SGA, whereas the effects of GH
treatment in GHD children are inconsistent. Some studies
showed no changes in TC and HDL cholesterol during short-
term GH treatment (45), whereas others found a decrease in
TC (46) or an increase in HDL cholesterol (47). In the present
study, TC, LDL cholesterol, and the atherogenic index de-
creased significantly during the first year of GH treatment
and remained stable thereafter, whereas HDL cholesterol did
not change during GH treatment. In a study evaluating the
effects of lipid profiles, the atherogenic index was the most
efficient predictor of coronary heart diseases in adults (48).
We found similar patterns in the GHD children as in the
non-GHD children. Similar changes in lipids were seen in the
children who remained prepubertal throughout the entire
study period as in the total study group. Thus, the start of
puberty during treatment cannot explain the changes in the
lipid profiles. In healthy children, no age-related change in
TC was observed between 5 and 10 yr of age, but TC de-
creased between 10 and 16 yr in boys, as well as in girls (33).
During the first year of GH treatment most children were
younger then 10 year of age. It is, therefore, likely that the
changes, particularly seen in the first year of treatment, are
not age related but due to GH. Thus, GH treatment seems to
have a beneficial effect on lipid metabolism in children with
short stature born SGA.
Although the increment in height sd-score was higher in
the children receiving GH treatment with 6 IU/m2zday com-
pared with 3 IU/m2zday, no differences were found between
the two GH dosages groups regarding the change in BMI,
skinfold thicknesses, BP, and lipids. To assess whether the
changes in body composition, BP, and lipids during GH
treatment were dependent on the baseline endogenous GH
status, we divided the total group in GHD and non-GHD
children by using the Dutch definition of GH deficiency
(peak GH secretion, ,10 mg/L during two GH tests). Com-
pared to North America, our definition is quite liberal. Before
GH treatment, BMI, skinfold, and BP sd-scores, as well as the
lipid levels, were not significantly different between GHD
and non-GHD children. During GH treatment, however, the
changes in the skinfold sd-score and BP sd-score were
slightly, but significantly, greater in the GHD than in the
non-GHD children, resulting in similar values after 6 yr of
GH treatment in both groups.
In our opinion, it is reassuring that our data show that
long-term GH treatment does not seem to have a negative
effect on BP and lipids. However, follow-up of these children
into adolescence is warranted because problems might arise
later in life. Another reason for long-term follow-up is the
evaluation of metabolic changes and changes in body com-
position after discontinuation of GH treatment, as described
previously in young GHD adults (49).
In conclusion, untreated children with short stature born
SGA either with or without GH deficiency are lean and have
a higher systolic BP, but normal diastolic BP and normal
lipids compared with healthy peers. During long-term con-
tinuous GH treatment with 3 or 6 IU/m2zday, the BMI nor-
malized without overall changes in sc fat compared with
healthy controls, whereas the BP sd-score and the athero-
genic index decreased significantly, indicating that GH treat-
ment has at least up to 6 yr of positive instead of negative
effects on these parameters. In view of the reported higher
risk of cardiovascular diseases in later life in children born
SGA, additional research into adulthood remains warranted.
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